Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Axitinib + PF-06801591 + SGN-TGT|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Axitinib||Inlyta||AG-013736|AG013736||KIT Inhibitor 52 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 33||Inlyta (axitinib) inhibits the VEGFRs, PDGFR, and KIT, potentially resulting in decreased angiogenesis and reduced tumor growth (PMID: 16027439, PMID: 25709499). Inlyta (axitinib) is approved for renal cell carcinoma (FDA.gov).|
|PF-06801591||PF06801591|PF 06801591|Sasanlimab||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 86||PF-06801591 (sasanlimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32847983).|
|SGN-TGT||SGN TGT|SEA-TGT|SGNTGT||TIGIT Antibody 14||SGN-TGT is a nonfucosylated monoclonal antibody targeting the immune checkpoint inhibitor TIGIT that binds to its target on tumor-infiltrating lymphocytes, inhibiting the interaction of TIGIT with CD112 and CD155 and enhancing the interaction of CD112 and CD155 with CD226 expressed on immune cells, which may lead to activation of the anti-tumor immune response (NCI Drug Dictionary; Annals of Oncology. 2020 Sep 1;31:S729-30).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04585815||Phase Ib/II||Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591||A Study of Sasanlimab With Other Therapies in People With Non-small Cell Lung Cancer||Recruiting||USA | CAN | BEL||3|